CABOTEGRAVIR\RILPIVIRINE: 5,026 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
5,026
Total FAERS Reports
101 (2.0%)
Deaths Reported
224
Hospitalizations
5,026
As Primary/Secondary Suspect
23
Life-Threatening
16
Disabilities
First Report: 10121111 · Latest Report: 20250919
What Are the Most Common CABOTEGRAVIR\RILPIVIRINE Side Effects?
#1 Most Reported
Product dose omission issue
655 reports (13.0%)
#2 Most Reported
Injection site pain
545 reports (10.8%)
#3 Most Reported
Viral load increased
428 reports (8.5%)
All CABOTEGRAVIR\RILPIVIRINE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Product dose omission issue | 655 | 13.0% | 0 | 32 |
| Injection site pain | 545 | 10.8% | 1 | 13 |
| Viral load increased | 428 | 8.5% | 0 | 3 |
| Off label use | 366 | 7.3% | 1 | 2 |
| Pain | 256 | 5.1% | 1 | 11 |
| Virologic failure | 255 | 5.1% | 0 | 2 |
| Product use in unapproved therapeutic environment | 239 | 4.8% | 0 | 0 |
| Pathogen resistance | 202 | 4.0% | 0 | 1 |
| Product storage error | 168 | 3.3% | 0 | 2 |
| Inappropriate schedule of product administration | 162 | 3.2% | 1 | 36 |
| Product complaint | 158 | 3.1% | 0 | 0 |
| Injection site nodule | 153 | 3.0% | 0 | 0 |
| Blood hiv rna increased | 125 | 2.5% | 0 | 1 |
| Fatigue | 123 | 2.5% | 2 | 11 |
| Wrong technique in device usage process | 109 | 2.2% | 0 | 2 |
| Viral mutation identified | 106 | 2.1% | 0 | 1 |
| Condition aggravated | 103 | 2.1% | 1 | 8 |
| Exposure during pregnancy | 99 | 2.0% | 0 | 0 |
| Pyrexia | 99 | 2.0% | 1 | 14 |
| Depression | 92 | 1.8% | 0 | 9 |
Who Reports CABOTEGRAVIR\RILPIVIRINE Side Effects? Age & Gender Data
Gender: 28.4% female, 71.6% male. Average age: 44.8 years. Most reports from: US. View detailed demographics →
Is CABOTEGRAVIR\RILPIVIRINE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 0 |
| 2018 | 2 | 0 | 0 |
| 2019 | 3 | 0 | 0 |
| 2021 | 110 | 0 | 7 |
| 2022 | 389 | 7 | 12 |
| 2023 | 519 | 16 | 25 |
| 2024 | 605 | 23 | 31 |
| 2025 | 286 | 15 | 36 |
What Is CABOTEGRAVIR\RILPIVIRINE Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 2,678 |
| Hiv infection | 2,044 |
| Illness | 52 |
| Hiv test | 35 |
| Acquired immunodeficiency syndrome | 19 |
| Antiretroviral therapy | 18 |
| Hiv carrier | 15 |
| Hiv test positive | 15 |
| Asymptomatic hiv infection | 14 |
| Hiv infection cdc group iii | 14 |
CABOTEGRAVIR\RILPIVIRINE vs Alternatives: Which Is Safer?
CABOTEGRAVIR\RILPIVIRINE vs CABOZANTINIB
CABOTEGRAVIR\RILPIVIRINE vs CABOZANTINIB S-MALATE
CABOTEGRAVIR\RILPIVIRINE vs CAFFEINE
CABOTEGRAVIR\RILPIVIRINE vs CALASPARGASE PEGOL
CABOTEGRAVIR\RILPIVIRINE vs CALASPARGASE PEGOL-MKNL
CABOTEGRAVIR\RILPIVIRINE vs CALCIFEDIOL
CABOTEGRAVIR\RILPIVIRINE vs CALCIPOTRIENE
CABOTEGRAVIR\RILPIVIRINE vs CALCITONIN
CABOTEGRAVIR\RILPIVIRINE vs CALCITONIN SALMON
CABOTEGRAVIR\RILPIVIRINE vs CALCITRIOL
Official FDA Label for CABOTEGRAVIR\RILPIVIRINE
Official prescribing information from the FDA-approved drug label.